{"filing":{"accession_number":"0001437749-26-021833","cik":"0000072444","ticker":"VXRT","company_name":"Vaxart, Inc.","form":"8-K","filing_date":"2026-06-26","report_date":null,"primary_document":"vxrt20260626_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/72444/000143774926021833/vxrt20260626_8k.htm"},"events":[{"id":14233,"run_id":12658,"accession_number":"0001437749-26-021833","anchor_item_number":"1.01","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"Vaxart entered into Modification No. 7 to its BARDA funding agreement, establishing approximately $345 million in total available funding (down from $461 million) with $68 million in firm fixed price amounts and the remainder for cost reimbursement, plus an additional $29 million release for trial completion and analyses. This modification creates a material direct financial obligation and represents a binding commitment of government funding to support the company's Phase 2b COVID-19 vaccine trial.","company_name":"Vaxart, Inc.","ticker":"VXRT","filing_date":"2026-06-26","form":"8-K","submitted_at":null,"items":[{"id":11601,"accession_number":"0001437749-26-021833","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Vaxart entered into Modification No. 7 to a BARDA funding agreement, which establishes a material direct financial obligation. The modification specifies approximately $345 million in total funding available (down from $461 million), with approximately $68 million in firm fixed price amounts and the remainder for cost reimbursement, plus an additional $29 million release for trial completion and analyses. While this is government funding rather than traditional debt issuance, it creates a binding financial obligation under Item 1.01 (Entry into a Material Definitive Agreement) and represents a material increase in the company's available capital resources to fund its Phase 2b COVID-19 vaccine trial.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T20:11:51.961629+00:00","company_name":"","ticker":null,"filing_date":""},{"id":11602,"accession_number":"0001437749-26-021833","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Vaxart announced a contract modification with BARDA that reduces overall funding from approximately $461 million to $345 million (a $116 million decrease) following a 50% reduction in trial participants due to a BARDA partial termination in August 2025. While this involves government funding and a clinical trial, it is primarily an operational/strategic update regarding the scope and funding of an ongoing Phase 2b COVID-19 vaccine trial, with the modification enabling release of $29 million for data analysis and reporting of trial results. This is material to investors as it affects the company's clinical development program and available resources, but does not fit neatly into the specific financial or governance categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T20:11:51.961629+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11601,"accession_number":"0001437749-26-021833","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Vaxart entered into Modification No. 7 to a BARDA funding agreement, which establishes a material direct financial obligation. The modification specifies approximately $345 million in total funding available (down from $461 million), with approximately $68 million in firm fixed price amounts and the remainder for cost reimbursement, plus an additional $29 million release for trial completion and analyses. While this is government funding rather than traditional debt issuance, it creates a binding financial obligation under Item 1.01 (Entry into a Material Definitive Agreement) and represents a material increase in the company's available capital resources to fund its Phase 2b COVID-19 vaccine trial.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T20:11:51.961629+00:00","company_name":"Vaxart, Inc.","ticker":"VXRT","filing_date":"2026-06-26"},{"id":11602,"accession_number":"0001437749-26-021833","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Vaxart announced a contract modification with BARDA that reduces overall funding from approximately $461 million to $345 million (a $116 million decrease) following a 50% reduction in trial participants due to a BARDA partial termination in August 2025. While this involves government funding and a clinical trial, it is primarily an operational/strategic update regarding the scope and funding of an ongoing Phase 2b COVID-19 vaccine trial, with the modification enabling release of $29 million for data analysis and reporting of trial results. This is material to investors as it affects the company's clinical development program and available resources, but does not fit neatly into the specific financial or governance categories.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-26T20:11:51.961629+00:00","company_name":"Vaxart, Inc.","ticker":"VXRT","filing_date":"2026-06-26"}]}